… one-fifth of the patients are children and adolescents. Out of 463 MEFV mutation-specified …
trial to explore the safety and efficacy of anakinra in colchicine-resistant FMF patients. It was …

… Anakinra and canakinumab were effective in patient refractory … Eight patients diagnosed as
colchicine resistant participated … children and adolescents with familial Mediterranean fever: …

… Twenty-seven per cent of patients were previously treated with biologics, mainly anakinra. …
associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. Ann …

… to investigate the safety and efficacy of IL-1-blocking therapy in colchicine-resistant FMF and
in … The treatment of colchicine-resistant FMF with anakinra and canakinumab was safe and …

… study were to assess the efficacy of rilonacept in decreasing … have been used for
colchicine-resistant FMF, including tumor … anakinra, 4 weeks for etanercept, and 8 weeks for …

… -1 receptor antagonist anakinra for colchicine-resistant FMF … series of colchicine-resistant
Familial Mediterranean fever patients … nine adolescent and adult FMF patients. They treated the …

… The prominent response of our patient to IL-1Ra anakinra … Anakinra had rapid, sustained
effects on our patient. The … We believe that the favourable response of our patient to anakinra …

… trial with anakinra in FMF patients who were colchicine resistant was published (…
colchicine-resistant familial Mediterranean fever. They also showed that IL-1 inhibition is an …

… achieved good outcomes about effectiveness and safety [20]. Anakinra and canakinumab
are … Anakinra and canakinumab succeeded in complete remission in more than two-third of …

… colchicine-resistant FMF patients and patients with amyloidosis during childhood and adolescent
… After anakinra or canakinumab therapy, their lives completely changed without any or …